Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cell Therapy for Ischemic Stroke

Athersys, Inc. today announced that it has concluded patient enrollment of its Phase 2 clinical study involving administration of Athersys' MultiStem cell therapy to ischemic stroke patients. The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the safety and efficacy of MultiStem therapy in subjects suffering moderate to moderate-severe ischemic strokes.

http://www.globenewswire.com/news-release/2014/12/29/694082/10113535/en/Athersys-Finishes-Enrollment-of-Phase-2-Study-of-MultiStem-R-Cell-Therapy-for-Ischemic-Stroke.html